Chronic inflammatory bowel diseases

Clinical information

The most important chronic inflammatory bowel diseases (CIBD) include ulcerative colitis (UC) and Crohn's disease (CD).

UC belongs to the genetically predisposed CIBD with autoimmune reactions against the mucosa and submucosa of the colon or rectum and increased immune reactions against the intestinal flora. The inflammation spreads continuously from the rectum, that is from the anal region upwards.

CD is classified as an autoimmune disease of the intestinal mucosa and is among the CIBD with a high recurrence rate. The chronic granulomatous inflammation, which can affect the whole digestive tract from the oral cavity to the anus, is found in most cases only in the lower small intestine (terminal ileum) and the large intestine (colon), very rarely in the oesophagus and mouth. A discontinuous, segmental attack on the intestinal mucosa, with several sections of the intestine being affected simultaneously, is characteristic for CD.

Diagnostics

Differential diagnostics are, along with targeted diagnostics, essential for the differentiated diagnosis of CIBD. The high diagnostic requirements are met by IIFT single assays as well as by various highly specific IIFT mosaics (CIBD profiles), which have been developed especially for the serological diagnosis of the autoimmunological bowel diseases CD and UC.

Autoantibodies against acinus cells of the exocrine pancreas are a reliable marker for CD. They have a high disease-specific significance due to their organ specificity, disease association and frequently high serum concentration. Due to the fact that the inflammation of the intestinal wall in CD is caused by the autoantigens contained in the pancreas secretion, particularly the proteoglycans CUZD1 and GP2, the determination of autoantibodies against the pancreas antigens rPAg1 (CUZD1) and/or PAg2 (GP2) using IIFT represents a new dimension in the serological diagnosis of CD. Antibodies against Saccharomyces cerevisiae (ASCA) enrich the serological diagnosis of CD by a further specific parameter.

Autoantibodies against intestinal goblet cells, which occur exclusively in UC, are pathognomonic markers for this autoimmune disease. The target antigen responsible for UC has not yet been exactly identified. The serological determination of autoantibodies against DNA-bound lactoferrin contributes significantly to the diagnosis of CIBD, particularly of UC.

Selected Products

Method
Parameter
Substrate
Species
IIFT
antibodies against DNA-bound lactoferrin (pANCA)
(LFS ab control)
IIFT
DNA-bound lactoferrin (pANCA)
ANCA negative
LFS granulocytes
HSS granulocytes
(2 BIOCHIPs per field)
human
EUROLINE
Autoimmune Gastrointestinal Diseases IgG
(tissue transglutaminase (endomysium),
gliadin-analogue fusion peptide (GAF-3X),
parietal cell antigen (PCA) separately
Intrinsic factor, mannan (ASCA))
EUROLINE
EUROLINE
Autoimmune Gastrointestinal Diseases IgA
(tissue transglutaminase (endomysium), gliadin-analogue
fusion peptide (GAF-3X), mannan (ASCA))
EUROLINE
IIFT
intestinal goblet cells
intestinal tissue
monkey
IIFT
antibodies against intestinal goblet cells
(ulcerative colitis; UC IgA control)
IIFT
antibodies against intestinal goblet cells
(ulcerative colitis; UC IgG control)
IIFT
intestinal goblet cells
goblet cells
EU 80
IIFT
antibodies against pancreas acini
(CUZD1 control; associated with Crohn's disease)
IIFT
Crohn's Disease Mosaic 1
pancreas antigen rPAg1 (CUZD1)
pancreas antigen rPAg2 (GP2)
3 BIOCHIPs per field:
transfected cells
transfected cells
control transfection

EU 90
EU 90
EU 90
IIFT
Crohn's Disease Mosaic 2
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
2 BIOCHIPs per field:
transfected cells
control transfection

EU 90
EU 90
IIFT
CIBD Screen 3
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
intestinal goblet cells
3 BIOCHIPs per field:
transfected cells
goblet cells
control transfection

EU 90
EU 80
EU 90
IIFT
CIBD Profile 3
upper row:
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)

intestinal goblet cells
pANCA
DNA-bound lactoferrin (pANCA)
ANCA negative
bottom row:
Saccharomyces cerevisiae


transfected cells
control transfection
goblet cells
granulocytes (EOH)
LFS granulocytes
HSS granulocytes

fungal smear


EU 90
EU 90
EU 80
human
human
human

S. cerevisiae
IIFT
CIBD Screen 6
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
intestinal goblet cells
Saccharomyces cerevisiae
cANCA, pANCA, GS-ANA
5 BIOCHIPs per field:
transfected cells
goblet cells
fungal smear
granulocytes (EOH)
control transfection

EU 90
EU 80
S. cerevisiae
human
EU 90
IIFT
CIBD Profile 7
upper row:
pancreas ag rPAg1(CUZD1) / rPAg2(GP2)
intestinal goblet cells
pANCA

bottom row:
Saccharomyces cerevisiae


transfected cells
goblet cells
granulocytes (EOH)
control transfection

fungal smear


EU 90
EU 80
human
EU 90

S. cerevisiae
IIFT
antibodies against pancreas secretion
(GP2 control; associated with Crohn's disease)
IIFT
antibodies against Saccharomyces cerevisiae
IgA positive control
fungal
smear
Saccharomyces
cerevisiae
IIFT
antibodies against Saccharomyces cerevisiae
IgG positive control
fungal
smear
Saccharomyces
cerevisiae
IIFT
Saccharomyces cerevisiae
negative control
ELISA
Saccharomyces cerevisiae
antigen-coated
microplate wells
IIFT
Saccharomyces cerevisiae
fungal
smear
Saccharomyces
cerevisiae
ELISA
MabTrack level adalimumab
ELISA
MabTrack anti-drug antibody adalimumab
ELISA
MabTrack level infliximab
ELISA
MabTrack anti-drug antibody infliximab
ELISA
calprotectin
determination in stool
antibody-coated
microplate wells
ChLIA
calprotectin
determination in stool
ChLIA
Control set
calprotectin
determination in stool
Back to top